Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Read more about Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Read more about Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Read more about Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Read more about Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Read more about Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Read more about Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Read more about Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT Read more about RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Read more about Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Read more about Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer